A study on haloperidol and risperidone induced metabolic derangements in patients with newly diagnosed schizophrenia
Keywords:Metabolic syndrome, Schizophrenia, Haloperidol, Risperidone, Atypical antipsychotic, Typical antipsychotic
Background: The occurrence of metabolic abnormalities in schizophrenic patients has been increased with the rampant use of second-generation antipsychotics. The aim and objective of this study is to compare the metabolic derangements induced by a typical antipsychotic: haloperidol and an atypical antipsychotic, risperidone in patients with newly diagnosed schizophrenia in a tertiary care hospital.
Methods: Out of 60 newly diagnosed schizophrenic patients, 30 patients received tablet haloperidol and the remaining 30 patients received tablet risperidone orally. The anthropometric measurements like height, weight, waist circumference was measured and blood investigations like fasting blood glucose level and fasting lipid profile were taken at baseline and at the end of 3 and 6 months of drug therapy. The metabolic derangements induced by the two antipsychotics were compared and analyzed at end of 3rd and 6th month using SPSS software version 16.
Results: At the end of 6th month statistically significant differences (p<0.05) were observed in weight, waist circumference, fasting blood sugar, fasting triglyceride and high-density lipoprotein level between the haloperidol and risperidone group on following the International Diabetic Federation (IDF) criteria of metabolic syndrome. Risperidone caused metabolic abnormalities in 13.3%, 4 patients whereas none of the patients in haloperidol group developed metabolic syndrome.
Conclusions: Hence it is concluded that the atypical antipsychotic risperidone has been associated with an increased risk of causing metabolic abnormalities than the typical antipsychotic haloperidol. Regular and periodic monitoring of the anthropometric and metabolic parameters in schizophrenic patients on antipsychotics especially the atypical antipsychotics is mandatory to prevent further complications.
Lawrence RE, First MB, Lieberman JA. Schizophrenia and Other Psychoses. In: Tasman A, Kay J, Riba MB (eds). Psychiatry. 4th edition, London: John Wiley & Sons; 2015: 791-798.
Schizophrenia JA. Course and Outcome. In: Gelder MG, Andreasen NC, Lopez-Ibor JL, Geddes JR (eds). New Oxford Textbook of Psychiatry. 2nd edition. New Delhi: Oxford University press; 2012: 568-572.
Standaert DG, Sung VM. Pharmacology of Dopaminergic Neurotransmission. In: Golan DE, Armstrong EJ, Armstrong AW, (eds). Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy, 4th edition. Philadelphia: Wolters Kluwer Health; 2017: 207-19.
Patel JK, Buckley PF, Woolson S, Hamer RM, McEvoy JP, Perkins DO, et al. Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study. Schizophr Res. 2009;111:9-16.
Mainar AS, Tamayo MB, Gutierrez JR, Artieda RN. Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: a cross-sectional assessment of a primary health care database. Eur Psychiatry. 2008;23:100-8.
Hert MD, Schreurs V, Sweers K, Eyck DV, Hanssens L, Sinko S, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review. Schizophr Res. 2008;101:295-303.
Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003;160:290-6.
Cohn T, Prud’homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: High prevalence of the metabolic syndrome. Can J Psychiatry. 2004;49:753-60.
McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19-32.
Hert MD, Winkel RV, Eyck DV, Hanssens L, Wampers M, Scheen A, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006;83:87-93.
Gautam S, Meena PS. Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics. Indian J Psychiatry. 2011;53:128-33.
Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, Ramirez-Bonilla ML, Alvarez-Jimenez M, Pelayo-Teran JM, et al. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: Findings of a randomized clinical trial in a drug naïve population. Schizophr Res. 2008;99:13–22.
Saddichha S, Manjunatha N, Ameen S, Akhtar S. Metabolic syndrome in first episode schizophrenia-a randomized double-blind controlled, short-term prospective study. Schizophr Res. 2008;101:266-72.
Saddichha S, Manjunatha N, Ameen S, Akhtar S. Diabetes and schizophrenia – effect of disease or drug? Results from a randomized,double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatr Scand. 2008;117:342-7.
Barnwal A, Oza B, Patel V. Metabolic side effects of antipsychotic agents: a prospective study in a teaching hospital. NHL J Med Sci. 2012;1(1):23-6.
Grover S, Aggarwal M, Dutt A, Chakrabarti S, Avasthi A, Kulhara P, et al. Prevalence of metabolic syndrome in patients with schizophrenia in India. Psychiatry Res. 2012;200:1035-7.
Chadda RK, Ramshankar P, Deb KS, Sood M. Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients. J Pharmacol Pharmacother. 2013;4(3):176-86.